Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier

• Published in: Molecules (Basel, Switzerland) Switzerland), 2019-09, Vol.24 (18), p.3369
• Main Authors: Chen, Gongsen, Luo, Juyuan, Cai, Mengru, Qin, Liuying, Wang, Yibo, Gao, Lili, Huang, Pingqing, Yu, Yingchao, Ding, Yangming, Dong, Xiaoxv, Yin, Xingbin, Ni, Jian
• Format: Article
• Language: English
• Subjects: Adsorption; Annexin V; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - chemistry; Antitumor; Antitumor activity; Apoptosis; Apoptosis - drug effects; Bioavailability; Biocompatibility; Biotechnology; Breast cancer; Cancer therapies; Cell Line, Tumor; Cell Survival - drug effects; Controlled release; Cytotoxicity; Diterpenes, Kaurane - administration & dosage; Diterpenes, Kaurane - chemistry; Drug carriers; Drug Carriers - chemistry; Drug delivery; Drug Delivery Systems; Drug Liberation; Fourier analysis; Fourier transforms; FTIR spectrometers; HepG2 cells; Humans; Infrared analysis; Infrared spectrometers; Ligands; Light scattering; Liver cancer; Metal-Organic Frameworks; Methods; Models, Molecular; MOF-5; Molecular Conformation; Molecular Structure; Nanoparticles; Nitrates; Organic loading; Oridonin; Particle size; Photon correlation spectroscopy; Scanning electron microscopy; Solvents; Spectrum Analysis; Sustained release; Thermogravimetric analysis; Thermogravimetry; X-ray diffraction
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules24183369

Oridonin (ORI) is a natural active ingredient with strong anticancer activity. But its clinical use is restricted due to its poor water solubility, short half-life, and low bioavailability. The aim of this study is to utilize the metal organic framework material MOF-5 to load ORI in order to improve its release characteristics and bioavailability. Herein, MOF-5 was synthesized by the solvothermal method and direct addition method, and characterized by Scanning Electron Microscopy (SEM), X-Ray Diffraction (XRD), Fourier Transform Infrared Spectrometer (FTIR), Thermogravimetric Analysis (TG), Brunauer-Emmett-Teller (BET), and Dynamic Light Scattering (DLS), respectively. MOF-5 prepared by the optimal synthesis method was selected for drug-loading and in vitro release experiments. HepG2 cells were model cells. MTT assay, 4',6-diamidino-2-phenylindole (DAPI) staining and Annexin V/PI assay were used to detect the biological safety of blank carriers and the anticancer activity of drug-loaded materials. The results showed that nano-MOF-5 prepared by the direct addition method had complete structure, uniform size and good biocompatibility, and was suitable as an ORI carrier. The drug loading of ORI@MOF-5 was 52.86% ± 0.59%. The sustained release effect was reliable, and the cumulative release rate was about 87% in 60 h. ORI@MOF-5 had significant cytotoxicity (IC50:22.99 μg/mL) and apoptosis effect on HepG2 cells. ORI@MOF-5 is hopeful to become a new anticancer sustained release preparation. MOF-5 has significant potential as a drug carrier material.